vs
Side-by-side financial comparison of Equillium, Inc. (EQ) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.
Equillium, Inc. is the larger business by last-quarter revenue ($4.4M vs $3.9M, roughly 1.1× Opus Genetics, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -52.3%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -29.7%).
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory diseases with high unmet medical needs. It advances pipeline candidates targeting immune system dysregulation, primarily catering to patients and healthcare providers across the United States.
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
EQ vs IRD — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.4M | $3.9M |
| Net Profit | $-5.8M | — |
| Gross Margin | — | — |
| Operating Margin | -107.0% | — |
| Net Margin | -131.9% | — |
| Revenue YoY | -52.3% | -10.2% |
| Net Profit YoY | -147.4% | 53.0% |
| EPS (diluted) | $-0.16 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $3.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.4M | ||
| Q4 24 | $4.4M | $4.3M | ||
| Q3 24 | $12.2M | $3.9M | ||
| Q2 24 | $13.9M | $1.1M | ||
| Q1 24 | $10.7M | $1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-17.5M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-8.2M | ||
| Q4 24 | $-5.8M | — | ||
| Q3 24 | $-7.0K | $-7.5M | ||
| Q2 24 | $468.0K | $-7.8M | ||
| Q1 24 | $-2.7M | $-7.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | -269.9% | ||
| Q2 25 | — | -309.0% | ||
| Q1 25 | — | -227.2% | ||
| Q4 24 | -107.0% | — | ||
| Q3 24 | -5.6% | -207.1% | ||
| Q2 24 | -0.7% | -748.9% | ||
| Q1 24 | -26.1% | -450.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | -566.9% | ||
| Q2 25 | — | -257.5% | ||
| Q1 25 | — | -187.5% | ||
| Q4 24 | -131.9% | — | ||
| Q3 24 | -0.1% | -194.6% | ||
| Q2 24 | 3.4% | -698.3% | ||
| Q1 24 | -25.6% | -415.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.25 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $-0.24 | ||
| Q4 24 | $-0.16 | — | ||
| Q3 24 | $0.00 | $-0.29 | ||
| Q2 24 | $0.01 | $-0.30 | ||
| Q1 24 | $-0.08 | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.1M | $45.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $19.1M | $15.3M |
| Total Assets | $25.6M | $50.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $45.1M | ||
| Q3 25 | — | $30.8M | ||
| Q2 25 | — | $32.4M | ||
| Q1 25 | — | $41.8M | ||
| Q4 24 | $18.1M | $30.3M | ||
| Q3 24 | $15.4M | $36.6M | ||
| Q2 24 | $11.1M | $41.4M | ||
| Q1 24 | $11.6M | $47.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $6.0M | ||
| Q2 25 | — | $17.5M | ||
| Q1 25 | — | $5.1M | ||
| Q4 24 | $19.1M | $6.7M | ||
| Q3 24 | $23.2M | $34.3M | ||
| Q2 24 | $22.4M | $40.6M | ||
| Q1 24 | $21.1M | $46.1M |
| Q4 25 | — | $50.2M | ||
| Q3 25 | — | $36.1M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $48.2M | ||
| Q4 24 | $25.6M | $36.9M | ||
| Q3 24 | $34.5M | $40.4M | ||
| Q2 24 | $42.9M | $44.8M | ||
| Q1 24 | $43.6M | $51.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.3M | $-35.3M |
| Free Cash FlowOCF − Capex | $-3.3M | — |
| FCF MarginFCF / Revenue | -75.2% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-35.3M | ||
| Q3 25 | — | $-6.2M | ||
| Q2 25 | — | $-10.3M | ||
| Q1 25 | — | $-9.0M | ||
| Q4 24 | $-3.3M | $-25.6M | ||
| Q3 24 | $-7.7M | $-5.1M | ||
| Q2 24 | $730.0K | $-7.3M | ||
| Q1 24 | $-8.8M | $-5.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-3.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $668.0K | — | ||
| Q1 24 | $-8.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -75.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | -82.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.56× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
